CD19 CAR-T cells

also known as CD19 chimeric antigen T cells

Cell therapy targets CD19, CD22 via depletion

Developed for: B-cell acute lymphoblastic leukemia · systemic lupus erythematosus · acute lymphoblastic leukemia · B-cell non-Hodgkin lymphoma · diffuse large B-cell lymphoma · mantle cell lymphoma · adult acute lymphoblastic leukemia · autoimmune disease
+15 more
· B-cell adult acute lymphocytic leukemia · B-cell chronic lymphocytic leukemia · B-cell neoplasm · follicular lymphoma · precursor B-cell acute lymphoblastic leukemia · Burkitt lymphoma · childhood acute lymphoblastic leukemia · chronic lymphocytic leukemia/small lymphocytic lymphoma · large B-cell lymphoma · leukemia · lymphoma · myasthenia gravis · non-Hodgkin lymphoma · primary central nervous system lymphoma · refractory plasma cell neoplasm
Investigated by: Beijing GoBroad Hospital · Zhejiang University · Chongqing Precision Biotech Co., Ltd · Institute of Hematology & Blood Diseases Hospital, China · Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd · The First Affiliated Hospital of Soochow University
+44 more
· Yake Biotechnology Ltd. · Juventas Cell Therapy Ltd. · National University of Malaysia · The General Hospital of Western Theater Command · Xuzhou Medical University · Avalon GloboCare Corp. · Belarusian Research Center for Pediatric Oncology, Hematology and Immunology · Bioceltech Therapeutics, Ltd. · CSPC Pharmaceutical Group Limited · Central People's Hospital of Zhanjiang · Chengdu Ucello Biotechnology Co., Ltd. · China Immunotech (Beijing) Biotechnology Co., Ltd. · City of Hope Medical Center · First Affiliated Hospital of Guangxi Medical University · First Hospital of China Medical University · Gaia Science · Hebei Senlang Biotechnology Inc., Ltd. · Hebei Yanda Ludaopei Hospital · Henan Province Engineering Technology Research Center of Immunological Precision Medicine and Artificial Intelligence Application, Luoyang, China · Hrain Biotechnology Co., Ltd. · Memorial Sloan Kettering Cancer Center · National Cancer Institute (NCI) · PersonGen BioTherapeutics (Suzhou) Co., Ltd. · Plutonet Sdn Bhd · Ruijin Hospital · Shanghai Changzheng Hospital · Shanghai Jiao Tong University School of Medicine · Shanghai Liquan Hospital · Shanghai Longyao Biotechnology Inc., Ltd. · Sheba Medical Center · ShenZhen Cell Valley · The Affiliated Hospital of Xuzhou Medical University · The Children's Hospital of Zhejiang University School of Medicine · The First Affiliated Hospital of Nanchang University · The First Affiliated Hospital of Zhengzhou University · The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine · Third Military Medical University · Tianjin Mycure Medical Technology Co., Ltd · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · University College, London · University Hospital Heidelberg · Xinqiao Hospital of Chongqing · Zhaxin Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai · Zhujiang Hospital

Trials 40

today NCT06326008 · Ph 1 NCT07331467 · Ph 1 NCT07277504 · Ph 0 NCT07252336 · Ph 2 NCT07233642 · Ph 1 NCT07193667 · not/applicable NCT07161193 · Ph 1/2 NCT07072494 · Ph 1/2 NCT06710717 · Ph 1 NCT06688799 · Ph 1/2 NCT06585514 · Ph 1/2 NCT06608342 · Ph 2 NCT06464185 · Ph 1/2 NCT06343090 · not/applicable NCT05828225 · Ph 1 NCT05755828 · Ph 2 NCT05239676 · Ph 0 NCT06220097 · Ph 2 NCT04556266 · Ph 1 NCT04443829 · Ph 1 NCT04661020 · Ph 2 NCT05333302 · Ph 1 NCT04271800 · Ph 1/2 NCT04194931 · Ph 1 NCT03952923 · Ph 1 NCT04271410 · Ph 1/2 NCT04237428 · not/applicable NCT03937544 · Ph 2/3 NCT03676504 · Ph 1/2 NCT03671460 · Ph 1 NCT05381662 · Ph 1/2 NCT03574168 · Ph 1 NCT03298828 · Ph 1 NCT03275493 · Ph 1/2 NCT03207178 · Ph 1/2 NCT03064269 · Ph 1 NCT02772198 · Ph 1/2 NCT02975687 · Ph 1 NCT02652910 · Ph 1/2 NCT01318317 · Ph 1/2

201120122013201420152016201720182019202020212022202320242025202620272028202920302031203220332034203520362037203820392040204120422043

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 02 trials
Phase 0	NCT07277504	Dec 2025 → Dec 2030 expected	B-cell adult acute lymphocytic leukemia	The General Hospital of Western Theater Command	Not yet recruiting	No outcome recorded
Phase 0	NCT05239676	Feb 2022 → Dec 2024	lymphoma	Zhejiang University	Unknown	No outcome recorded
Phase 115 trials
Phase 1	NCT06326008	Mar → Jun 2026 overdue	B-cell acute lymphoblastic leukemia	Beijing GoBroad Hospital	Recruiting	No outcome recorded
Phase 1	NCT07331467	Jan → Jul 2026 overdue	systemic lupus erythematosus	Chongqing Precision Biotech Co., Ltd	Recruiting	No outcome recorded
Phase 1	NCT07233642	Nov 2025 → May 2026 overdue	systemic lupus erythematosus	The Children's Hospital of Zhejiang University School of Medicine	Recruiting	No outcome recorded
Phase 1	NCT06710717	Jan 2025 → Dec 2028 expected	systemic lupus erythematosus	National University of Malaysia	Recruiting	No outcome recorded
Phase 1	NCT05828225	Apr 2023 → Apr 2026	myasthenia gravis	Zhejiang University	Unknown	No outcome recorded
Phase 1	NCT04556266	Jul 2021 → Mar 2022	B-cell non-Hodgkin lymphoma, leukemia	Memorial Sloan Kettering Cancer Center	Withdrawn	No outcome recorded Stop: Enrollment
Phase 1	NCT04443829	Mar 2021 → Dec 2024 overdue	primary central nervous system lymphoma	University College, London	Active not recruiting	No outcome recorded
Phase 1	NCT05333302	Oct 2020 → Dec 2024 overdue	B-cell acute lymphoblastic leukemia	Belarusian Research Center for Pediatric Oncology, Hematology and Immunology	Recruiting	No outcome recorded
Phase 1	NCT04194931	Dec 2019 → Dec 2020	refractory plasma cell neoplasm	The First Affiliated Hospital of Nanchang University	Unknown	No outcome recorded
Phase 1	NCT03952923	Aug 2019 → Jan 2021	B-cell neoplasm	Hebei Yanda Ludaopei Hospital	Completed	No outcome recorded
Phase 1	NCT03671460	Sep 2018 → Jan 2020	B-cell acute lymphoblastic leukemia	Tianjin Mycure Medical Technology Co., Ltd	Unknown	No outcome recorded
Phase 1	NCT03574168	Jul 2018 → Dec 2019	B-cell acute lymphoblastic leukemia	Bioceltech Therapeutics, Ltd.	Unknown	No outcome recorded
Phase 1	NCT03298828	Nov 2017 → Oct 2020	Burkitt lymphoma, acute lymphoblastic leukemia	Third Military Medical University	Unknown	No outcome recorded
Phase 1	NCT03064269	Mar 2017 → Dec 2024	B-cell acute lymphoblastic leukemia	Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd	Unknown	No outcome recorded
Phase 1	NCT02975687	Nov 2016 → Dec 2018	B-cell adult acute lymphocytic leukemia	Institute of Hematology & Blood Diseases Hospital, China	Completed	No outcome recorded

Phase 1/214 trials
Phase 1/2	NCT07161193	Sep 2025 → Aug 2027 expected	autoimmune disease	Hebei Senlang Biotechnology Inc., Ltd.	Not yet recruiting	No outcome recorded
Phase 1/2	NCT07072494	Jul 2025 → Mar 2027 expected	acute lymphoblastic leukemia	Zhujiang Hospital	Recruiting	No outcome recorded
Phase 1/2	NCT06688799	Nov 2024 → Mar 2026 overdue	autoimmune disease	Beijing GoBroad Hospital	Recruiting	No outcome recorded
Phase 1/2	NCT06585514	Oct 2024 → Sep 2026 overdue	lupus nephritis, systemic lupus erythematosus	Beijing GoBroad Hospital	Recruiting	No outcome recorded
Phase 1/2	NCT06464185	Apr 2024 → Mar 2026 overdue	B-cell non-Hodgkin lymphoma	Institute of Hematology & Blood Diseases Hospital, China	Active not recruiting	No outcome recorded
Phase 1/2	NCT04271800	Dec 2019 → Dec 2023	B-cell chronic lymphocytic leukemia	Chongqing Precision Biotech Co., Ltd	Unknown	No outcome recorded
Phase 1/2	NCT04271410	Jun 2019 → Dec 2023	B-cell chronic lymphocytic leukemia, diffuse large B-cell lymphoma	Chongqing Precision Biotech Co., Ltd	Unknown	No outcome recorded
Phase 1/2	NCT03676504	Sep 2018 → Dec 2026 expected	adult acute lymphoblastic leukemia, childhood acute lymphoblastic leukemia, chronic lymphocytic leukemia/small lymphocytic lymphoma, diffuse large B-cell lymphoma +2	University Hospital Heidelberg	Recruiting	No outcome recorded
Phase 1/2	NCT05381662	Aug 2018 → Aug 2024	acute lymphoblastic leukemia	Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd	Unknown	No outcome recorded
Phase 1/2	NCT03275493	Jul 2017 → Dec 2024	B-cell acute lymphoblastic leukemia	Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd	Unknown	No outcome recorded
Phase 1/2	NCT03207178	Mar 2017 → Feb 2019	B-cell neoplasm	Shanghai Longyao Biotechnology Inc., Ltd.	Unknown	No outcome recorded
Phase 1/2	NCT02772198	Nov 2016 → Jul 2022	precursor B-cell acute lymphoblastic leukemia	Sheba Medical Center	Unknown	No outcome recorded
Phase 1/2	NCT02652910	Dec 2015 → Jun 2019	diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma	Xinqiao Hospital of Chongqing	Unknown	No outcome recorded
Phase 1/2	NCT01318317	Oct 2011 → Oct 2013 overdue	mantle cell lymphoma	City of Hope Medical Center	Active not recruiting	No outcome recorded

Phase 25 trials
Phase 2	NCT07252336	Nov 2025 → Nov 2027 expected	—	Zhejiang University	Recruiting	No outcome recorded
Phase 2	NCT06608342	Jun 2024 → May 2026 overdue	adult acute lymphoblastic leukemia	Institute of Hematology & Blood Diseases Hospital, China	Recruiting	No outcome recorded
Phase 2	NCT05755828	Dec 2022 → Dec 2024	B-cell non-Hodgkin lymphoma	The Affiliated Hospital of Xuzhou Medical University	Unknown	No outcome recorded
Phase 2	NCT06220097	Feb 2022 → Aug 2024 overdue	B-cell acute lymphoblastic leukemia	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	Active not recruiting	No outcome recorded
Phase 2	NCT04661020	Dec 2020 → Dec 2026 expected	large B-cell lymphoma	Zhejiang University	Recruiting	No outcome recorded
Phase 2/31 trial
Phase 2/3	NCT03937544	Mar 2019 → Jan 2027 expected	B-cell acute lymphoblastic leukemia, precursor B-cell acute lymphoblastic leukemia	National University of Malaysia	Recruiting	No outcome recorded
Phase not applicable3 trials
—	NCT07193667	Oct 2025 → Sep 2027 expected	—	ShenZhen Cell Valley	Recruiting	No outcome recorded
—	NCT06343090	Apr 2024 → Dec 2042 expected	B-cell acute lymphoblastic leukemia	Beijing GoBroad Hospital	Recruiting	No outcome recorded
—	NCT04237428	May → Jun 2019	non-Hodgkin lymphoma	PersonGen BioTherapeutics (Suzhou) Co., Ltd.	Unknown	No outcome recorded

News releases announcing trial results or a regulatory action · 1

Date	Issuer	Release
2021-12-10	Caring Cross	Results Caring Cross Announces Publication in Nature Communications Demonstrating Effectiveness of Place-of-Care Manufacture of Anti-CD19 CAR T Cells for Treatment of B-cell Malignancies caringcross.org ↗ For NHL complete responders, the one-year survival rate was 92.9%, with a median duration of response yet to be reached.

All press releases naming this drug 1 release

Date	Issuer	Release
2021-12-10	Caring Cross	Caring Cross Announces Publication in Nature Communications Demonstrating Effectiveness of Place-of-Care Manufacture of Anti-CD19 CAR T Cells for Treatment of B-cell Malignancies caringcross.org ↗

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 41 sources stand behind the page.

Field	Value	Cited text
Known as	CD19 CAR-T cells	“CD3-CD20 bispecific antibody-based therapy in combination with CD19-CAR-T cells for the treatment of relapsed and refractory B-cell Non-Hodgkin's （B-NHL） lymphoma.” NCT06464185 ↗ 39 “Engineered TCM-derived CD19 CAR T cells were infused 2 days after HSCT at doses of 25 to 200 × 10(6) in a single infusion.” PMID 27118452 ↗ Apr 2016 “Peripheral blood mononuclear cells for the production of CD19 CAR T cells and CD22 CAR T cells are collected from donors.” NCT06326008 ↗ “CD19 CAR-T cells were prepared from peripheral lymphocytes of NHL patients with PR after 3 to 4 courses of chemotherapy” NCT05755828 ↗ “modified T cells' (or CD19 chimeric antigen T cells, also called CD19 CAR T cells) that target the B cell marker” NCT04556266 ↗ “Autologous CD19-CAR T cells were transfused +7 days after autologous hematopoietic stem cell transplantation” NCT06608342 ↗ “Autologous CD19 CAR-T cells and CD20 CAR-T cells with average 1-5\*10\^6 cells/kg body weight,separately.” NCT03207178 ↗ “Patients with Refractory Autoimmune Diseases will receive CD19 CAR T cells.” NCT07161193 ↗ “Murine-derived CD19 CAR T cells” NCT06343090 ↗ NCT04271800 ↗ NCT03574168 ↗ Show 29 more sources
Known as	CD19 chimeric antigen T cells	“modified T cells' (or CD19 chimeric antigen T cells, also called CD19 CAR T cells) that target the B cell marker” NCT04556266 ↗
Action	Deplete	“CAR-Ts with shRNA-IL-6 gene knockdown migrated into the CNS, eradicated leukemic cells” PMID 32745961 ↗ Jul 2020
Modality	Cell therapy	“using ex vivo-expanded autologous central memory-enriched T cells (TCM) transduced with lentivirus expressing CD19-specific chimeric antigen receptors (CARs).” PMID 27118452 ↗ Apr 2016
Route	Intravenous	“CD19 CAR T cells will be administered by i.v. injection” NCT02975687 ↗
Target	CD19	“CD19-specific CARs” NCT02652910 ↗